CN118139616A - 用于制备脂质纳米颗粒的高通量方法及其用途 - Google Patents

用于制备脂质纳米颗粒的高通量方法及其用途 Download PDF

Info

Publication number
CN118139616A
CN118139616A CN202280070682.6A CN202280070682A CN118139616A CN 118139616 A CN118139616 A CN 118139616A CN 202280070682 A CN202280070682 A CN 202280070682A CN 118139616 A CN118139616 A CN 118139616A
Authority
CN
China
Prior art keywords
solution
lnp
payload
lipid
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280070682.6A
Other languages
English (en)
Chinese (zh)
Inventor
范俣辰
C-W·延
张珂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN118139616A publication Critical patent/CN118139616A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN202280070682.6A 2021-10-26 2022-10-26 用于制备脂质纳米颗粒的高通量方法及其用途 Pending CN118139616A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272136P 2021-10-26 2021-10-26
US63/272,136 2021-10-26
PCT/US2022/078710 WO2023076945A1 (en) 2021-10-26 2022-10-26 High-throughput methods for preparing lipid nanoparticles and uses thereof

Publications (1)

Publication Number Publication Date
CN118139616A true CN118139616A (zh) 2024-06-04

Family

ID=86158549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280070682.6A Pending CN118139616A (zh) 2021-10-26 2022-10-26 用于制备脂质纳米颗粒的高通量方法及其用途

Country Status (12)

Country Link
US (1) US20240390287A1 (https=)
EP (1) EP4422606A4 (https=)
JP (1) JP2024541897A (https=)
KR (1) KR20240090304A (https=)
CN (1) CN118139616A (https=)
AR (1) AR127469A1 (https=)
AU (1) AU2022376919A1 (https=)
CA (1) CA3233239A1 (https=)
IL (1) IL311945A (https=)
MX (1) MX2024004733A (https=)
TW (1) TW202333653A (https=)
WO (1) WO2023076945A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120722759A (zh) * 2025-08-28 2025-09-30 深圳市一五零生命科技有限公司 复方利多卡因纳米凝胶的制备工艺优化方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120392779A (zh) * 2015-06-15 2025-08-01 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
WO2017223135A1 (en) * 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
US20230157955A1 (en) * 2020-01-08 2023-05-25 Puretech Lyt, Inc. Vesicle compositions for oral delivery
TW202237068A (zh) * 2020-12-09 2022-10-01 美商建南德克公司 製備脂質奈米顆粒的高通量方法及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120722759A (zh) * 2025-08-28 2025-09-30 深圳市一五零生命科技有限公司 复方利多卡因纳米凝胶的制备工艺优化方法及系统
CN120722759B (zh) * 2025-08-28 2025-11-21 深圳市一五零生命科技有限公司 复方利多卡因纳米凝胶的制备工艺优化方法及系统

Also Published As

Publication number Publication date
US20240390287A1 (en) 2024-11-28
AR127469A1 (es) 2024-01-31
WO2023076945A1 (en) 2023-05-04
KR20240090304A (ko) 2024-06-21
IL311945A (en) 2024-06-01
EP4422606A4 (en) 2025-09-17
WO2023076945A9 (en) 2025-02-13
CA3233239A1 (en) 2023-05-04
JP2024541897A (ja) 2024-11-13
EP4422606A1 (en) 2024-09-04
TW202333653A (zh) 2023-09-01
AU2022376919A1 (en) 2024-03-21
MX2024004733A (es) 2024-05-10

Similar Documents

Publication Publication Date Title
US20220249695A1 (en) Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US20230330023A1 (en) High-throughput methods for preparing lipid nanoparticles and uses thereof
Zhou et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA)
EP3673898A1 (en) Method of producing lipid nanoparticles for drug delivery
Weyermann et al. Comparison of antisense oligonucleotide drug delivery systems
JP2002521423A (ja) 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
JP2001511440A (ja) 層状構造の、中性あるいは陰性グローバル電荷を持つ安定粒状複合体
US20120301539A1 (en) Method of producing coated fine particles
US20240390287A1 (en) High-throughput methods for preparing lipid nanoparticles and uses thereof
US20120121670A1 (en) Polyarginine nanocapsules
Hameed et al. Liposomes like advanced drug carriers: from fundamentals to pharmaceutical applications
KR20020012215A (ko) 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체
KR20230022415A (ko) 지질-중합체 조성물 및 사용 방법
US20190328903A1 (en) Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor
MacLachlan et al. Diffusible‐PEG‐Lipid Stabilized Plasmid Lipid Particles
HK40110520A (zh) 用於制备脂质纳米颗粒的高通量方法及其用途
US9937127B2 (en) Method of producing fine particles surface-modified with water-soluble substance
HK40101719A (zh) 用於制备脂质纳米颗粒的高通量方法及其用途
JPWO2005092389A1 (ja) 複合粒子および被覆複合粒子
Sarker Sculpted amphiphilic liposomal particles for modifiable medicinal applications
EP0555317B1 (en) Phospholipid analogue vesicle with a succinimidyl moiety
EP4674431A1 (en) Lipid nanoparticles, pharmaceutical composition, and production method for lipid nanoparticles
Patel et al. Potential of surface functionalized nanoparticles for improved therapy of refractory central nervous system disorders
CN121152620A (zh) 用含聚噁唑啉-脂质缀合物的纳米颗粒靶向抗原呈递细胞
Ojarudi et al. Lipid Nanoparticle Formulations for Targeted Anticancer Drug Delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110520

Country of ref document: HK